The Patient Activation Measure: a validation study in a neurological population

被引:34
|
作者
Packer, Tanya L. [1 ]
Kephart, George [2 ]
Ghahari, Setareh [3 ,4 ]
Audulv, Asa [1 ,5 ]
Versnel, Joan [1 ]
Warner, Grace [1 ]
机构
[1] Dalhousie Univ, Sch Occupat Therapy, Halifax, NS B3H 4R2, Canada
[2] Dalhousie Univ, Community Hlth & Epidemiol, Halifax, NS B3H 4R2, Canada
[3] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada
[4] Univ Social Welf & Rehabil Sci, Dept Occupat Therapy, Tehran, Iran
[5] Mid Sweden Univ, Dept Nursing, Sundsvall, Sweden
关键词
Chronic disease management; Measurement; Validation; Neurological conditions; Patient activation; PAM-13; SHORT-FORM; SELF-MANAGEMENT; MEASURE PAM; EMPLOYEES HEALTH; PEOPLE; INDIVIDUALS; TRANSLATION; SCLEROSIS; OUTCOMES; QUALITY;
D O I
10.1007/s11136-014-0908-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
To assess the validity of the Patient Activation Measure (PAM13) of patient activation in persons with neurological conditions. "The Everyday Experience of Living with and Managing a Neurological Condition" (The LINC study) surveyed 948 adults with neurological conditions residing in Canada in 2011 and 2012. Using data for 722 respondents who met coding requirements for the PAM-13, we examined the properties of the measure using principle components analysis, inter-item correlations and Cronbach's alpha to assess unidimensionality and internal consistency. Rasch modeling was used to assess item performance and scaling. Construct validity was assessed by calculating associations between the PAM and known correlates. PAM-13 provides a suitably reliable and valid instrument for research in patients with neurological conditions, but scaling problems may yield measurement error and biases for those with low levels of activation. This is of particular importance when used in clinical settings or for individual client care. Our study also suggests that measurement of activation may benefit from tailoring items and scaling to specific diagnostic groups such as people with neurological conditions, thus allowing the PAM-13 to recognize unique attributes and management challenges in those conditions. The PAM-13 is an internally reliable and valid tool for research purposes. The use of categorical activation "level" in clinical settings should be done with caution.
引用
收藏
页码:1587 / 1596
页数:10
相关论文
共 50 条
  • [1] The Patient Activation Measure: a validation study in a neurological population
    Tanya L. Packer
    George Kephart
    Setareh Ghahari
    Åsa Audulv
    Joan Versnel
    Grace Warner
    Quality of Life Research, 2015, 24 : 1587 - 1596
  • [2] Validation of the Brazilian Version of the Patient Activation Measure 13
    Cunha, Cristiane Martins
    Previde Teixeira da Cunha, Debora Cristine
    Manzato, Rafaela de Oliveira
    Nepomuceno, Eliane
    da Silva, Dirceu
    Spadoti Dantas, Rosana Aparecida
    JOURNAL OF NURSING MEASUREMENT, 2019, 27 (01) : 97 - 113
  • [3] Psychometric properties of the Patient Activation Measure-13 among out-patients waiting for mental health treatment: A validation study in Norway
    Moljord, Inger Elise O.
    Lara-Cabrera, Mariela L.
    Perestelo-Perez, Lilisbeth
    Rivero-Santana, Amado
    Eriksen, Lasse
    Linaker, Olav M.
    PATIENT EDUCATION AND COUNSELING, 2015, 98 (11) : 1410 - 1417
  • [4] Psychometric evaluation of the German version of the patient activation measure (PAM13)
    Zill, Joerdis M.
    Dwinger, Sarah
    Kriston, Levente
    Rohenkohl, Anja
    Haerter, Martin
    Dirmaier, Joerg
    BMC PUBLIC HEALTH, 2013, 13
  • [5] Validation of the Patient Activation Measure (PAM-13) among adults with cardiac conditions in Singapore
    Ngooi, Bi Xia
    Packer, Tanya L.
    Kephart, George
    Warner, Grace
    Koh, Karen Wei Ling
    Wong, Raymond Ching Chiew
    Lim, Serene Peiying
    QUALITY OF LIFE RESEARCH, 2017, 26 (04) : 1071 - 1080
  • [6] Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study
    Zimbudzi, Edward
    Lo, Clement
    Ranasinha, Sanjeeva
    Fulcher, Gregory R.
    Jan, Stephen
    Kerr, Peter G.
    Polkinghorne, Kevan R.
    Russell, Grant
    Walker, Rowan G.
    Zoungas, Sophia
    BMJ OPEN, 2017, 7 (10):
  • [7] A Systematic Review of the Reliability and Validity of the Patient Activation Measure Tool
    Ng, Qin Xiang
    Liau, Matthias Yi Quan
    Tan, Yong Yi
    Tang, Ansel Shao Pin
    Ong, Clarence
    Thumboo, Julian
    Lee, Chien Earn
    HEALTHCARE, 2024, 12 (11)
  • [8] Validation of the patient activation measure in a multiple sclerosis clinic sample and implications for care
    Stepleman, Lara
    Rutter, Marie-Christine
    Hibbard, Judith
    Johns, Lisa
    Wright, Dustin
    Hughes, Mary
    DISABILITY AND REHABILITATION, 2010, 32 (19) : 1558 - 1567
  • [9] Patient activation in Europe: an international comparison of psychometric properties and patients' scores on the short form Patient Activation Measure (PAM-13)
    Rademakers, Jany
    Maindal, Helle Terkildsen
    Steinsbekk, Aslak
    Gensichen, Jochen
    Brenk-Franz, Katja
    Hendriks, Michelle
    BMC HEALTH SERVICES RESEARCH, 2016, 16 : 1 - 7
  • [10] Patient and treatment characteristics associated with patient activation in patients undergoing hemodialysis: a cross-sectional study
    Van Bulck, Liesbet
    Claes, Kathleen
    Dierickx, Katrien
    Hellemans, Annelies
    Jamar, Sofie
    Smets, Sven
    Van Pottelbergh, Gijs
    BMC NEPHROLOGY, 2018, 19